Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy

Med Mol Morphol. 2023 Jun;56(2):85-93. doi: 10.1007/s00795-023-00348-x. Epub 2023 Feb 7.

Abstract

In this review, we discuss the possibility of the vitamin D metabolizing enzyme CYP24A1 being a therapeutic target for various tumors including breast, colorectal and prostate tumors. Given the pleiotropic cellular activity of vitamin D, its deficiency impairs its physiological function in target cells and results in various pathologies including cancer. In addition, accumulated data have shown that elevated expression of CYP24A1 promotes carcinogenesis in various cancer subtypes by decreasing the bioavailability of vitamin D metabolites. Thus, we propose the potential feasibility of vitamin D metabolism-blocking therapy in various types of human malignancies that express constitutive CYP24A1.

Keywords: Anticancer drugs; Cancer; Oncogenic property; Vitamin D; Vitamin D metabolism-blocking therapy; Vitamin D metabolizing enzyme CYP24A1.

Publication types

  • Review

MeSH terms

  • Feasibility Studies
  • Humans
  • Male
  • Neoplasms* / drug therapy
  • Vitamin D* / pharmacology
  • Vitamin D* / therapeutic use
  • Vitamin D3 24-Hydroxylase / genetics

Substances

  • Vitamin D3 24-Hydroxylase
  • Vitamin D